Does the media prefer IMNM or HALO?

In the previous week, Halozyme Therapeutics had 15 more articles in the media than Immunome. MarketBeat recorded 19 mentions for Halozyme Therapeutics and 4 mentions for Immunome. Halozyme Therapeutics' average media sentiment score of 0.60 beat Immunome's score of 0.51 indicating that Halozyme Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Immunome 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Halozyme Therapeutics 6 Very Positive mention(s) 1 Positive mention(s) 11 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer IMNM or ARWR?

In the previous week, Arrowhead Pharmaceuticals had 11 more articles in the media than Immunome. MarketBeat recorded 15 mentions for Arrowhead Pharmaceuticals and 4 mentions for Immunome. Immunome's average media sentiment score of 0.51 beat Arrowhead Pharmaceuticals' score of 0.14 indicating that Immunome is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Immunome 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Arrowhead Pharmaceuticals 3 Very Positive mention(s) 1 Positive mention(s) 8 Neutral mention(s) 2 Negative mention(s) 1 Very Negative mention(s) Neutral

Which has better valuation and earnings, KRYS or IMNM?

Krystal Biotech has higher revenue and earnings than Immunome. Immunome is trading at a lower price-to-earnings ratio than Krystal Biotech, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Krystal Biotech $389.13M 25.61 $204.83M $7.98 42.19 Immunome $6.94M 392.29 -$212.39M -$2.53 N/A

Does the media favor KRYS or IMNM?

In the previous week, Immunome had 1 more articles in the media than Krystal Biotech. MarketBeat recorded 4 mentions for Immunome and 3 mentions for Krystal Biotech. Krystal Biotech's average media sentiment score of 1.65 beat Immunome's score of 0.51 indicating that Krystal Biotech is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Krystal Biotech 3 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Immunome 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has stronger valuation & earnings, ABVX or IMNM?

Immunome has higher revenue and earnings than Abivax. Abivax is trading at a lower price-to-earnings ratio than Immunome, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Abivax N/A N/A -$380.27M -$5.21 N/A Immunome $6.94M 392.29 -$212.39M -$2.53 N/A

Is ABVX or IMNM more profitable?

Immunome's return on equity of -50.56% beat Abivax's return on equity. Company Net Margins Return on Equity Return on Assets Abivax N/A -99.02% -70.26% Immunome N/A -50.56% -46.93%

Does the media favor ABVX or IMNM?

In the previous week, Abivax had 2 more articles in the media than Immunome. MarketBeat recorded 6 mentions for Abivax and 4 mentions for Immunome. Abivax's average media sentiment score of 0.51 beat Immunome's score of 0.51 indicating that Abivax is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Abivax 0 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Immunome 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to IMNM or KYMR?

In the previous week, Kymera Therapeutics had 3 more articles in the media than Immunome. MarketBeat recorded 7 mentions for Kymera Therapeutics and 4 mentions for Immunome. Immunome's average media sentiment score of 0.51 beat Kymera Therapeutics' score of 0.50 indicating that Immunome is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Immunome 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Kymera Therapeutics 2 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Immunome (IMNM) Competitors

$23.97 +0.04 (+0.17%)

Closing price 09/18/2026 04:00 PM Eastern

Extended Trading

$24.05 +0.08 (+0.33%)

As of 09/18/2026 07:30 PM Eastern

Compare

IMNM vs. HALO, ARWR, KRYS, ABVX, and KYMR

Should you buy Immunome stock or one of its competitors? Immunome's main competitors and comparable companies include Halozyme Therapeutics (HALO), Arrowhead Pharmaceuticals (ARWR), Krystal Biotech (KRYS), Abivax (ABVX), and Kymera Therapeutics (KYMR). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Immunome compare to Halozyme Therapeutics?

Immunome (NASDAQ:IMNM) and Halozyme Therapeutics (NASDAQ:HALO) are both healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, risk, earnings, analyst recommendations, valuation, dividends, media sentiment and institutional ownership.

In the previous week, Halozyme Therapeutics had 15 more articles in the media than Immunome. MarketBeat recorded 19 mentions for Halozyme Therapeutics and 4 mentions for Immunome. Halozyme Therapeutics' average media sentiment score of 0.60 beat Immunome's score of 0.51 indicating that Halozyme Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Immunome	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Halozyme Therapeutics	6 Very Positive mention(s)	1 Positive mention(s)	11 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

44.6% of Immunome shares are held by institutional investors. Comparatively, 97.8% of Halozyme Therapeutics shares are held by institutional investors. 7.2% of Immunome shares are held by company insiders. Comparatively, 2.5% of Halozyme Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Halozyme Therapeutics has a net margin of 24.86% compared to Immunome's net margin of 0.00%. Halozyme Therapeutics' return on equity of 260.98% beat Immunome's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Immunome	N/A	-50.56%	-46.93%
Halozyme Therapeutics	24.86%	260.98%	23.91%

Immunome has a beta of 2.13, meaning that its stock price is 113% more volatile than the broader market. Comparatively, Halozyme Therapeutics has a beta of 0.88, meaning that its stock price is 12% less volatile than the broader market.

Immunome presently has a consensus target price of $34.64, indicating a potential upside of 44.50%. Halozyme Therapeutics has a consensus target price of $91.20, indicating a potential downside of 18.90%. Given Immunome's stronger consensus rating and higher possible upside, equities analysts clearly believe Immunome is more favorable than Halozyme Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Immunome	1 Sell rating(s)	0 Hold rating(s)	12 Buy rating(s)	0 Strong Buy rating(s)	2.85
Halozyme Therapeutics	1 Sell rating(s)	3 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.62

Halozyme Therapeutics has higher revenue and earnings than Immunome. Immunome is trading at a lower price-to-earnings ratio than Halozyme Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Immunome	$6.94M	392.29	-$212.39M	-$2.53	N/A
Halozyme Therapeutics	$1.66B	7.67	$316.89M	$3.35	33.57

Summary

Halozyme Therapeutics beats Immunome on 10 of the 16 factors compared between the two stocks.

How does Immunome compare to Arrowhead Pharmaceuticals?

Immunome (NASDAQ:IMNM) and Arrowhead Pharmaceuticals (NASDAQ:ARWR) are both mid-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their media sentiment, institutional ownership, analyst recommendations, valuation, profitability, earnings, dividends and risk.

Immunome has a beta of 2.13, suggesting that its stock price is 113% more volatile than the broader market. Comparatively, Arrowhead Pharmaceuticals has a beta of 1.28, suggesting that its stock price is 28% more volatile than the broader market.

In the previous week, Arrowhead Pharmaceuticals had 11 more articles in the media than Immunome. MarketBeat recorded 15 mentions for Arrowhead Pharmaceuticals and 4 mentions for Immunome. Immunome's average media sentiment score of 0.51 beat Arrowhead Pharmaceuticals' score of 0.14 indicating that Immunome is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Immunome	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Arrowhead Pharmaceuticals	3 Very Positive mention(s)	1 Positive mention(s)	8 Neutral mention(s)	2 Negative mention(s)	1 Very Negative mention(s)	Neutral

Immunome presently has a consensus price target of $34.64, indicating a potential upside of 44.50%. Arrowhead Pharmaceuticals has a consensus price target of $99.15, indicating a potential upside of 49.15%. Given Arrowhead Pharmaceuticals' higher probable upside, analysts clearly believe Arrowhead Pharmaceuticals is more favorable than Immunome.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Immunome	1 Sell rating(s)	0 Hold rating(s)	12 Buy rating(s)	0 Strong Buy rating(s)	2.85
Arrowhead Pharmaceuticals	1 Sell rating(s)	3 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.64

44.6% of Immunome shares are owned by institutional investors. Comparatively, 62.6% of Arrowhead Pharmaceuticals shares are owned by institutional investors. 7.2% of Immunome shares are owned by insiders. Comparatively, 3.6% of Arrowhead Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Immunome has a net margin of 0.00% compared to Arrowhead Pharmaceuticals' net margin of -47.79%. Immunome's return on equity of -50.56% beat Arrowhead Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Immunome	N/A	-50.56%	-46.93%
Arrowhead Pharmaceuticals	-47.79%	-60.06%	-17.37%

Arrowhead Pharmaceuticals has higher revenue and earnings than Immunome. Arrowhead Pharmaceuticals is trading at a lower price-to-earnings ratio than Immunome, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Immunome	$6.94M	392.29	-$212.39M	-$2.53	N/A
Arrowhead Pharmaceuticals	$829.45M	11.29	-$1.63M	-$2.25	N/A

Summary

Immunome beats Arrowhead Pharmaceuticals on 9 of the 16 factors compared between the two stocks.

How does Immunome compare to Krystal Biotech?

Krystal Biotech (NASDAQ:KRYS) and Immunome (NASDAQ:IMNM) are both healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their risk, media sentiment, dividends, institutional ownership, earnings, analyst recommendations, profitability and valuation.

In the previous week, Immunome had 1 more articles in the media than Krystal Biotech. MarketBeat recorded 4 mentions for Immunome and 3 mentions for Krystal Biotech. Krystal Biotech's average media sentiment score of 1.65 beat Immunome's score of 0.51 indicating that Krystal Biotech is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Krystal Biotech	3 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Immunome	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Krystal Biotech has higher revenue and earnings than Immunome. Immunome is trading at a lower price-to-earnings ratio than Krystal Biotech, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Krystal Biotech	$389.13M	25.61	$204.83M	$7.98	42.19
Immunome	$6.94M	392.29	-$212.39M	-$2.53	N/A

Krystal Biotech currently has a consensus price target of $365.40, suggesting a potential upside of 8.53%. Immunome has a consensus price target of $34.64, suggesting a potential upside of 44.50%. Given Immunome's higher probable upside, analysts clearly believe Immunome is more favorable than Krystal Biotech.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Krystal Biotech	0 Sell rating(s)	2 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.92
Immunome	1 Sell rating(s)	0 Hold rating(s)	12 Buy rating(s)	0 Strong Buy rating(s)	2.85

86.3% of Krystal Biotech shares are held by institutional investors. Comparatively, 44.6% of Immunome shares are held by institutional investors. 13.1% of Krystal Biotech shares are held by company insiders. Comparatively, 7.2% of Immunome shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Krystal Biotech has a beta of 0.54, meaning that its share price is 46% less volatile than the broader market. Comparatively, Immunome has a beta of 2.13, meaning that its share price is 113% more volatile than the broader market.

Krystal Biotech has a net margin of 54.82% compared to Immunome's net margin of 0.00%. Krystal Biotech's return on equity of 19.34% beat Immunome's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Krystal Biotech	54.82%	19.34%	17.65%
Immunome	N/A	-50.56%	-46.93%

Summary

Krystal Biotech beats Immunome on 12 of the 17 factors compared between the two stocks.

How does Immunome compare to Abivax?

Abivax (NASDAQ:ABVX) and Immunome (NASDAQ:IMNM) are both mid-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, institutional ownership, valuation, profitability, earnings, risk, analyst recommendations and media sentiment.

Abivax currently has a consensus price target of $156.38, indicating a potential upside of 48.88%. Immunome has a consensus price target of $34.64, indicating a potential upside of 44.50%. Given Abivax's stronger consensus rating and higher probable upside, analysts plainly believe Abivax is more favorable than Immunome.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Abivax	1 Sell rating(s)	1 Hold rating(s)	13 Buy rating(s)	1 Strong Buy rating(s)	2.88
Immunome	1 Sell rating(s)	0 Hold rating(s)	12 Buy rating(s)	0 Strong Buy rating(s)	2.85

Abivax has a beta of 0.96, suggesting that its stock price is 4% less volatile than the broader market. Comparatively, Immunome has a beta of 2.13, suggesting that its stock price is 113% more volatile than the broader market.

Immunome has higher revenue and earnings than Abivax. Abivax is trading at a lower price-to-earnings ratio than Immunome, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Abivax	N/A	N/A	-$380.27M	-$5.21	N/A
Immunome	$6.94M	392.29	-$212.39M	-$2.53	N/A

Immunome's return on equity of -50.56% beat Abivax's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Abivax	N/A	-99.02%	-70.26%
Immunome	N/A	-50.56%	-46.93%

In the previous week, Abivax had 2 more articles in the media than Immunome. MarketBeat recorded 6 mentions for Abivax and 4 mentions for Immunome. Abivax's average media sentiment score of 0.51 beat Immunome's score of 0.51 indicating that Abivax is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Abivax	0 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Immunome	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

47.9% of Abivax shares are held by institutional investors. Comparatively, 44.6% of Immunome shares are held by institutional investors. 7.2% of Immunome shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Summary

Immunome beats Abivax on 8 of the 15 factors compared between the two stocks.

How does Immunome compare to Kymera Therapeutics?

Immunome (NASDAQ:IMNM) and Kymera Therapeutics (NASDAQ:KYMR) are both mid-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, valuation, risk, profitability, dividends, earnings, analyst recommendations and media sentiment.

Immunome currently has a consensus target price of $34.64, indicating a potential upside of 44.50%. Kymera Therapeutics has a consensus target price of $131.63, indicating a potential upside of 11.78%. Given Immunome's higher probable upside, research analysts clearly believe Immunome is more favorable than Kymera Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Immunome	1 Sell rating(s)	0 Hold rating(s)	12 Buy rating(s)	0 Strong Buy rating(s)	2.85
Kymera Therapeutics	1 Sell rating(s)	2 Hold rating(s)	21 Buy rating(s)	1 Strong Buy rating(s)	2.88

In the previous week, Kymera Therapeutics had 3 more articles in the media than Immunome. MarketBeat recorded 7 mentions for Kymera Therapeutics and 4 mentions for Immunome. Immunome's average media sentiment score of 0.51 beat Kymera Therapeutics' score of 0.50 indicating that Immunome is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Immunome	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Kymera Therapeutics	2 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Immunome has higher earnings, but lower revenue than Kymera Therapeutics. Kymera Therapeutics is trading at a lower price-to-earnings ratio than Immunome, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Immunome	$6.94M	392.29	-$212.39M	-$2.53	N/A
Kymera Therapeutics	$39.21M	249.70	-$311.35M	-$3.24	N/A

Immunome has a net margin of 0.00% compared to Kymera Therapeutics' net margin of -285.33%. Kymera Therapeutics' return on equity of -21.22% beat Immunome's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Immunome	N/A	-50.56%	-46.93%
Kymera Therapeutics	-285.33%	-21.22%	-19.21%

44.6% of Immunome shares are owned by institutional investors. 7.2% of Immunome shares are owned by insiders. Comparatively, 16.0% of Kymera Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Immunome has a beta of 2.13, meaning that its stock price is 113% more volatile than the broader market. Comparatively, Kymera Therapeutics has a beta of 1.96, meaning that its stock price is 96% more volatile than the broader market.

Summary

Immunome beats Kymera Therapeutics on 9 of the 17 factors compared between the two stocks.

Get Immunome News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding IMNM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

IMNM vs. The Competition

Export

Metric	Immunome	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$2.72B	$3.91B	$7.25B	$13.13B
Dividend Yield	N/A	3.65%	2.57%	12.94%
P/E Ratio	-9.47	14.08	273.81	25.39
Price / Sales	392.29	1,407.75	692.78	109.00
Price / Cash	N/A	110.75	77.42	51.66
Price / Book	4.17	15.45	10.45	6.33
Net Income	-$212.39M	-$22.78M	$3.48B	$358.24M
7 Day Performance	-2.84%	-1.22%	0.88%	1.17%
1 Month Performance	-19.64%	-4.44%	-1.59%	-2.59%
1 Year Performance	155.27%	37.78%	18.08%	5.97%

Immunome Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
IMNM Immunome	3.0609 of 5 stars	$23.97 +0.2%	$34.64 +44.5%	+143.4%	$2.72B	$6.94M	N/A	177	Insider Trade High Trading Volume
HALO Halozyme Therapeutics	2.9481 of 5 stars	$107.33 -2.6%	$91.20 -15.0%	+46.6%	$12.16B	$1.40B	31.98	390	Trending News Insider Trade
ARWR Arrowhead Pharmaceuticals	2.809 of 5 stars	$85.85 -0.6%	$99.15 +15.5%	+111.0%	$12.09B	$829.45M	N/A	400
KRYS Krystal Biotech	3.3007 of 5 stars	$352.58 -1.6%	$365.40 +3.6%	+109.6%	$10.42B	$389.13M	44.10	210	Positive News
ABVX Abivax	2.3202 of 5 stars	$116.36 +1.4%	$156.50 +34.5%	+26.1%	$10.15B	N/A	N/A	61	Upcoming Earnings

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:IMNM) was last updated on 9/19/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Immunome (IMNM) Competitors

IMNM vs. HALO, ARWR, KRYS, ABVX, and KYMR

How does Immunome compare to Halozyme Therapeutics?

Summary

How does Immunome compare to Arrowhead Pharmaceuticals?

Summary

How does Immunome compare to Krystal Biotech?

Summary

How does Immunome compare to Abivax?

Summary

How does Immunome compare to Kymera Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

IMNM vs. The Competition

Immunome Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Immunome (IMNM) Competitors

IMNM vs. HALO, ARWR, KRYS, ABVX, and KYMR

How does Immunome compare to Halozyme Therapeutics?

Does the media prefer IMNM or HALO?

Do institutionals & insiders hold more shares of IMNM or HALO?

Is IMNM or HALO more profitable?

Which has more volatility and risk, IMNM or HALO?

Do analysts recommend IMNM or HALO?

Which has higher valuation & earnings, IMNM or HALO?

Summary

How does Immunome compare to Arrowhead Pharmaceuticals?

Which has more risk & volatility, IMNM or ARWR?

Does the media prefer IMNM or ARWR?

Do analysts prefer IMNM or ARWR?

Do institutionals & insiders believe in IMNM or ARWR?

Is IMNM or ARWR more profitable?

Which has preferable valuation and earnings, IMNM or ARWR?

Summary

How does Immunome compare to Krystal Biotech?

Does the media favor KRYS or IMNM?

Which has better valuation and earnings, KRYS or IMNM?

Do analysts rate KRYS or IMNM?

Do insiders & institutionals hold more shares of KRYS or IMNM?

Which has more volatility and risk, KRYS or IMNM?

Is KRYS or IMNM more profitable?

Summary

How does Immunome compare to Abivax?

Do analysts recommend ABVX or IMNM?

Which has more risk and volatility, ABVX or IMNM?

Which has stronger valuation & earnings, ABVX or IMNM?

Is ABVX or IMNM more profitable?

Does the media favor ABVX or IMNM?

Do insiders & institutionals believe in ABVX or IMNM?

Summary

How does Immunome compare to Kymera Therapeutics?

Do analysts recommend IMNM or KYMR?

Does the media refer more to IMNM or KYMR?

Which has stronger earnings and valuation, IMNM or KYMR?

Is IMNM or KYMR more profitable?

Do insiders and institutionals believe in IMNM or KYMR?

Which has more risk & volatility, IMNM or KYMR?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

IMNM vs. The Competition

Immunome Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools